PRMT5 and glioblastoma: As PRMT5 inhibitors were hits across many patient-derived GSCs, we sought to further investigate PRMT5 as a therapeutic target in GBM and in a larger cohort of primary patient-derived cell models to determine the potential breadth of its efficacy.